您的位置: 首页 > 2020年1月 第51卷 第1期 > 文字全文
2023年7月 第38卷 第7期11
目录

增生期糖尿病视网膜病变经全视网膜激光治疗的临床观察

Clinical observation of proliferative diabetic retinopathy treated with panretinal laser photocoagulation

来源期刊: 广州医药 | 55-58 发布时间:2021-11-28 收稿时间:2025/11/13 17:57:59 阅读量:14
作者:
关键词:
糖尿病视网膜病变全视网膜激光光凝视网膜厚度
Diabetes mellitusRetinopathyPanretinal laser photocoagulationRetinal thickness
DOI:
10.3969/j.issn.1000-8535.2020.01.013
收稿时间:
2019-08-11 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 探讨增生期糖尿病视网膜病变患者经全视网膜激光光凝治疗的临床效果。方法 选取2016年2月—2019年3月我院收治的增生期糖尿病视网膜病变患者97例,使用随机数表法分为观察组(49例)与对照组(48例)。对照组患者接受黄斑格栅样光凝治疗,观察组患者则接受全视网膜激光光凝治疗。收集2组患者手术前后视力、黄斑中心凹容积、乳头周边视网膜神经纤维层厚度及视网膜厚度变化情况等数据进行分析,并对比生活质量评分。结果 治疗前,2组患者视乳头旁视网膜神经纤维层厚度、黄斑中心凹容积以及视网膜厚度之间差异无统计学意义(P>0.05),具有可比性。接受不同治疗后,观察组患者上述3项指标均优于对照组患者(P<0.05)。观察组患者治疗总有效率为79.59%,高于对照组患者治疗总有效率59.18%(P<0.05)。此外,观察组患者在精细动作、调节能力、日常生活及远视力、光感和移动4个维度评分均高于对照组患者(P<0.05)。结论 与黄斑格栅样光凝治疗相比,增生期糖尿病视网膜病变患者接受全视网膜激光光凝治疗有助于改善其乳头周边视网膜神经纤维层厚度和黄斑区视网膜厚度,能够显著促进视力恢复,提升患者生活质量,疗效确切。
Objective To investigate the clinical effect of panretinal laser photocoagulation for proliferative diabetic retinopathy. Methods 97 cases of proliferative diabetic retinopathy in our hospital from Feb 2016 to Mar 2019 were enrolled in the study, and were divided into 2 groups randomly. The control group received treatment of macular grid photocoagulation, while the observation group received whole retina laser photocoagulation. Data of visual acuity, macular fovea volume, retinal nerve fiber layer thickness around nipple and retinal thickness before and after operation were collected and analyzed, and quality of life scores were compared. Results Before treatment, there was no significant difference in retinal nerve fiber layer thickness, macular fovea volume and retinal thickness between the two groups (P>0.05), which was comparable. After different treatments, the three indexes mentioned above in the observation group were better than those in the control group (P<0.05). The total effective rate of the observation group was 79.59%, which was higher than that of the control group (59.18%, P<0.05). In addition, the scores of fine motion, accommodation ability, daily life and distant vision, light perception and movement in the observation group were higher than those in the control group (P<0.05). Conclusion Compared with macular grid-like photocoagulation, panretinal laser photocoagulation may improve the retinal nerve fiber layer thickness around the nipple and macular retinal thickness in patients with proliferative diabetic retinopathy. It promotes the recovery of visual acuity, improves the quality of life of patients, and has definite curative effect.
1、 LIAO P L, LIN C H, LI C H, et al. Anti-inflammatory properties of shikonin contribute to improved early-stage diabetic retinopathy[J]. Sci Rep, 2017 (7):44985. LIAO P L, LIN C H, LI C H, et al. Anti-inflammatory properties of shikonin contribute to improved early-stage diabetic retinopathy[J]. Sci Rep, 2017 (7):44985.
2、 LEI X, ZENG G, ZHANG Y, et al. Association between homocysteine level and the risk of diabetic retinopathy: a systematic review and meta-analysis[J]. Diabetol Metab Syndr, 2018, 10(1):61. LEI X, ZENG G, ZHANG Y, et al. Association between homocysteine level and the risk of diabetic retinopathy: a systematic review and meta-analysis[J]. Diabetol Metab Syndr, 2018, 10(1):61.
3、 FUKUDA T, BOUCHI R, TAKEUCHI T, et al. Association of diabetic retinopathy with both sarcopenia and muscle quality in patients with type 2 diabetes: a cross-sectional study[J]. Bmj Open Dia Res Care, 2017, 5(1):e000404. FUKUDA T, BOUCHI R, TAKEUCHI T, et al. Association of diabetic retinopathy with both sarcopenia and muscle quality in patients with type 2 diabetes: a cross-sectional study[J]. Bmj Open Dia Res Care, 2017, 5(1):e000404.
4、 WANG L Z, CHEUNG C Y, TAPP R J, et al. Availability and variability in guidelines on diabetic retinopathy screening in Asian countries[J]. Br J Ophthalmol, 2017, 101(10):1352. WANG L Z, CHEUNG C Y, TAPP R J, et al. Availability and variability in guidelines on diabetic retinopathy screening in Asian countries[J]. Br J Ophthalmol, 2017, 101(10):1352.
5、 MELO L G N, MORALES P H, DRUMMOND K R G, et al. Current epidemiology of diabetic retinopathy in patients with type 1 diabetes: a national multicenter study in Brazil[J]. Bmc Public Health, 2018, 18(1):989. MELO L G N, MORALES P H, DRUMMOND K R G, et al. Current epidemiology of diabetic retinopathy in patients with type 1 diabetes: a national multicenter study in Brazil[J]. Bmc Public Health, 2018, 18(1):989.
6、 TUFAIL A, RUDISILL C, EGAN C, et al. Automated diabetic retinopathy image assessment software: diagnostic accuracy and cost-effectiveness compared with human graders[J]. Ophthalmol, 2017, 124(3):343-351. TUFAIL A, RUDISILL C, EGAN C, et al. Automated diabetic retinopathy image assessment software: diagnostic accuracy and cost-effectiveness compared with human graders[J]. Ophthalmol, 2017, 124(3):343-351.
7、 CARBONELL M, CASTELBLANCO E, VALLDEPERAS X, et al. Diabetic retinopathy is associated with the presence and burden of subclinical carotid atherosclerosis in type 1 diabetes[J]. Cardiovasc Diabetol, 2018,17(1):66. CARBONELL M, CASTELBLANCO E, VALLDEPERAS X, et al. Diabetic retinopathy is associated with the presence and burden of subclinical carotid atherosclerosis in type 1 diabetes[J]. Cardiovasc Diabetol, 2018,17(1):66.
8、 MASTROPASQUA R, TOTO L, MASTROPASQUA A, et al. Foveal avascular zone area and parafoveal vessel density measurements in different stages of diabetic retinopathy by optical coherence tomography angiography[J]. Int J Ophthalmol, 2017,10(10):67-73. MASTROPASQUA R, TOTO L, MASTROPASQUA A, et al. Foveal avascular zone area and parafoveal vessel density measurements in different stages of diabetic retinopathy by optical coherence tomography angiography[J]. Int J Ophthalmol, 2017,10(10):67-73.
9、 AREVALO J F, LASAVE A F, WU L, et al. intravitreal bevacizumab for proliferative diabetic retinopathy: results from the pan-american collaborative retina study group (pacores) at 24 months of follow-up[J]. Retina, 2017, 37(2):334-343. AREVALO J F, LASAVE A F, WU L, et al. intravitreal bevacizumab for proliferative diabetic retinopathy: results from the pan-american collaborative retina study group (pacores) at 24 months of follow-up[J]. Retina, 2017, 37(2):334-343.
10、 中华医学会眼科学会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2014年)[J]. 中华眼科杂志, 2014, 50(11):851-865. 中华医学会眼科学会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2014年)[J]. 中华眼科杂志, 2014, 50(11):851-865.
11、 GAO X, LI Y, WANG H, et al. Inhibition of HIF-1α decreases expression of pro-inflammatory IL-6 and TNF-α in diabetic retinopathy[J]. Acta Ophthalmologica, 2017, 95(8):45-48. GAO X, LI Y, WANG H, et al. Inhibition of HIF-1α decreases expression of pro-inflammatory IL-6 and TNF-α in diabetic retinopathy[J]. Acta Ophthalmologica, 2017, 95(8):45-48.
12、 CUI J, REN J P, CHEN D N, et al. Prevalence and associated factors of diabetic retinopathy in Beijing, China: a cross-sectional study[J]. Bmj Open, 2017, 7(8):e015473. CUI J, REN J P, CHEN D N, et al. Prevalence and associated factors of diabetic retinopathy in Beijing, China: a cross-sectional study[J]. Bmj Open, 2017, 7(8):e015473.
13、 SOLOMON S D, CHEW E, DUH E J, et al. Erratum. Diabetic retinopathy: a position statement by the American Diabetes Association.[J]. Diabetes Care, 2017, 40(9):412-418. SOLOMON S D, CHEW E, DUH E J, et al. Erratum. Diabetic retinopathy: a position statement by the American Diabetes Association.[J]. Diabetes Care, 2017, 40(9):412-418.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录